Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060074
Filing Date
2025-04-29
Accepted
2025-04-29 16:00:16
Documents
16
Period of Report
2025-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A crdf-20250429.htm   iXBRL DEF 14A 1421468
2 GRAPHIC img98646248_0.jpg GRAPHIC 140832
3 GRAPHIC img98646248_1.jpg GRAPHIC 303138
4 GRAPHIC img98646248_2.jpg GRAPHIC 305727
  Complete submission text file 0000950170-25-060074.txt   4320378

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20250429.xsd EX-101.SCH 8189
18 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20250429_htm.xml XML 382891
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35558 | Film No.: 25886935
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)